Duration of Antidepressant Maintenance Before Discontinuation in Anxiety Disorders
A patient in stable remission wants to taper off, using a maintenance timeline she read about for depression. The real evidence for anxiety disorders specifically points to a longer window — a distinct teaching point easy to blur.
Diane K., a 52-year-old woman, has been in stable remission from generalized anxiety disorder on escitalopram for two years, GAD-7 consistently under 4 at every visit for the past fourteen months, and asks at this visit whether she can start tapering off, reasoning that two years feels like a long time and that depression guidelines she read about online suggest six to twelve months of maintenance after remission is generally sufficient.
Those depression-specific discontinuation guidelines don't transfer cleanly to anxiety disorders. The relapse-prevention literature for GAD and panic disorder specifically suggests a longer maintenance period, often cited in the range of twelve to twenty-four months of sustained remission before attempting discontinuation is generally advisable, compared to the shorter windows more commonly discussed for depression — a distinct teaching point that's easy to blur if a patient, or a clinician, applies depression-era intuitions to an anxiety diagnosis without checking whether the evidence actually matches.
She's not resistant to hearing this — she says she genuinely assumed the guidance would be the same across conditions and is willing to wait longer if the reasoning is explained clearly, which the team takes as an invitation to walk through the actual relapse-rate data rather than simply stating a different number and moving on.
She mentions she found the six-to-twelve-month figure on a general mental-health website that didn't specify which diagnosis it was discussing, which the team notes as a common, genuinely easy mistake to make given how much online guidance treats "antidepressant maintenance" as a single undifferentiated topic rather than something that varies meaningfully by the condition actually being treated.
Choosing when a taper is appropriate
Her reasoning is understandable but based on the wrong evidence base — the six-to-twelve-month maintenance window she read about applies to depression specifically. The anxiety-disorder relapse literature, for GAD and panic disorder both, generally supports a longer maintenance period, often cited around twelve to twenty-four months of sustained remission, before a taper is advisable.
Worth explaining why the two conditions differ rather than just stating a different number — anxiety disorders tend to show a higher relapse rate after early discontinuation in the trial literature than depression does, which is the actual evidentiary basis for the longer recommended window, not an arbitrary distinction.
She's at fourteen months of sustained remission on top of roughly two years total treatment, which puts her within, not below, the generally recommended anxiety-specific maintenance range. A taper conversation is reasonable to have now, but framed accurately — she's not being overly cautious by continuing a bit longer, and she's not being denied something she's already earned by waiting the standard depression window.
Agreed: a gradual escitalopram taper will begin at this visit, now that her total remission duration falls within the anxiety-specific recommended maintenance window rather than the shorter depression-era figure she'd read about, with GAD-7 monitoring continued through the taper to catch early relapse signs.